Finding new clues to combat glioblastoma

Finding new clues to combat glioblastoma

Glioblastoma is an aggressive, killer disease. While victims of this fast-moving brain tumor comprise only about 15% of all people with brain cancer, its victims rarely survive more than a few years after diagnosis. But research scientists and doctors from the Case Western Reserve University School of Medicine, Case School of Engineering and Cleveland Clinic have blended two very different types of analysis to better understand and combat the brain cancer. The researchers used the tools of Artificial Intelligence (AI)--in this case, computer image analysis of the initial MRI scans taken of brain cancer patients--and compared that image analysis with genomic research to analyze the cancer. The result: A new and more accurate way to not only determine the relative life expectancy of glioblastoma victims--but identify who could be candidates for experimental clinical drug trials, said Pallavi Tiwari, an assistant professor of biomedical engineering at Case Western Reserve with dual appointments in the School of Medicine and Case School of Engineering. The study was led by Tiwari, along with Niha Beig, a PhD student in Tiwari's lab. Their research was published this month in Clinical Cancer Research , a journal of the American Association for Cancer Research. Unique study of MRI images, gene expression The AI model used by the researchers leveraged features from the region adjacent to the tumor, as well as inside the tumor to identify which patients had a poor prognosis, Pallavi said. Then, they used gene-expression information to shed light on which biological pathways were associated with those images. "Our results demonstrated that image features associated with poor prognosis were also linked with pathways that contribute to chemo-resistance in glioblastoma. This could have huge implications in designing personalized treatment decisions in glioblastoma patients, down the road." she said. While we're just at the beginning, this is a big step, and someday it could mean that if you have glioblastoma, you could know whether you'll respond to chemotherapy well or to immunotherapy, based on a patient's image and gene profiles." Manmeet Ahluwalia, MD, Miller Family Endowed Chair of NeuroOncology at the Burkhardt Brain Tumor and Neuro-Oncology Center at Cleveland Clinic, and a co-author of the study Related Stories



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More